300O - Assessment of the effectiveness of cervical cancer screening

Date 16 December 2016
Event ESMO Asia 2016 Congress
Session Gynaecological cancers
Topics Cervical Cancer
Aetiology, Epidemiology, Screening and Prevention
Presenter Rema Gvamichava
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors R. Gvamichava1, T. Beruchashvili2
  • 1Screeningt, National Screening Center, 0119 - Tbilisi/GE
  • 2Management, National Screening Center, 0119 - Tbilisi/GE



According to the US Center for Disease Control (CDC 2013), a reliable statistical tendency of decreasing cervical cancer incidence and mortality caused by this disease has beenrecorded in the United States over the recent 40 years that isrelated tohigh rate coverage of the female population by Pap-test screening. This tendency is proved by American Cancer Society (ACS, 2012).According to Gold M.A. (2006), 70-80% decrease of cervical cancer incidence has been achieved by Pap test screening in developed countries. According to the Norwegian Cervical Cancer Screening Program (NCCSP, 2014), screening has contributed to 25% decrease of cervical cancer incidence and 50% decrease of mortality caused by this disease in Norway.According to Nanda K. et al. (2000) data, in case of cervical cancer CIN 2/3, Pap test sensitivity and specificity vary within the range 47% - 62% and 60% - 85% correspondingly.


We have studied the cost-effectiveness of cervical cancer screening program, based on5 year period data (2010 – 2014): 66,324 women received gynecological examination and Pap test and 12,147 received colposcopy, targeted biopsy and morphological analysis. In 2013, 13 584 women received cervical cancer screening, among them 7,416 womenat the National Screening Center (NCC). The indicators of diagnostic effectiveness of gynecological examination, Pap test, colposcopy and combination of a Pap test and colposcopy have been studied based on NCC data with a purpose of assessment.


In 2013, the prevalence of cervical severe dysplasia(CIN3) and intraepithelial carcinoma (CIS) per 1,000 female population eligible for screening constituted 9,8% and cancer prevalence was 6,1%. The study has found that making of alterations in a screening guideline and re-adjusting of a target group from 25-59 to 30-64 age group will increase the number of detected cervical cancer cases and decrease needed expenditures: in case of 50% coverage of a target group by ∼93,000 GEL and by ∼130,000 GEL in case of 70% coverage.


Making of alterations to the screening guideline and readjusting of a target group to 3064 age group will significantly enhance the costeffectiveness of cervical cancer screening.

Clinical trial indentification

Legal entity responsible for the study

National Screening Center


National Screening Center


All authors have declared no conflicts of interest.